

ImmunoGen, Inc. Announces Webcast of Presentation at Bank of America Merrill Lynch 2011 Health Care Conference

WALTHAM, Mass., May 03, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that President and CEO, Daniel Junius, will present at the Bank of America Merrill Lynch 2011 Health Care Conference at 11:20 am PT/2:20 pm ET on May 10, 2011.

A live webcast of the presentation can be accessed through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of the presentation will be available at the same location for one week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently six TAP compounds in the clinic, with a wealth of clinical data reported with the technology. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Genentech (a member of the Roche Group), Novartis, and sanofi-aventis. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech. More information about ImmunoGen can be found at www.immunogen.com.

SOURCE: ImmunoGen, Inc.

For Investors:

ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com

or

For Media:

The Yates Network
Barbara Yates, 781-258-6153